News | Peripheral Artery Disease (PAD) | November 07, 2018

Lutonix 014 Drug-Coated Balloon Safe and Effective Below the Knee

Safety and efficacy results of IDE trial presented at VIVA 2018

Lutonix 014 Drug-Coated Balloon Safe and Effective Below the Knee

November 7, 2018 — The Lutonix Drug-Coated Balloon (DCB) showed statistically significant safety equivalence with a standard percutaneous transluminal angioplasty (PTA) catheter for the treatment of narrowed or obstructed arteries below the knee in recent trial results. The data were presented at the Vascular Interventional Advances (VIVA) 2018 annual conference, Nov. 5-8 in Las Vegas.

The Lutonix DCB investigational device exemption (IDE) clinical study is a prospective, global, multicenter, randomized, controlled trial comparing the Lutonix 014 DCB to standard angioplasty for the treatment of narrowed or obstructed arteries below the knee (BTK). The study used both proportional/binary and Kaplan Meier analyses to assess safety and efficacy. The primary safety endpoint — freedom from composite all-cause death, above the ankle or major reintervention of the treated limb through 30 days — was met showing statistically significant safety equivalence between the Lutonix 014 DCB and standard PTA catheter, in both the proportional/binary and Kaplan Meier analyses.

“The six-month clinical data from the Lutonix BTK trial represent the beginning of a paradigm shift in the treatment of patients with critical limb ischemia (CLI),” said Jihad Mustapha, M.D., FACC, FSCAI, Advanced Cardiac and Vascular Amputation Centers, Grand Rapids, Mich. “The initial results are extremely encouraging and give new hope to patients with CLI.”

The primary efficacy endpoint was assessed using a composite measurement of limbs saved from amputation and the openness of arteries, known as primary patency. By proportional/binary analysis, at six months there was an improvement in primary efficacy of 10.2 percent (DCB: 73.7 percent and PTA: 63.5 percent, p=0.0273, not-significant). The more commonly used Kaplan Meier analysis of the primary efficacy endpoint demonstrated a significant difference of 14.6 percent (DCB: 85.3 percent, PTA: 70.7 percent, p<0.001). Additional analyses are planned for 12, 24 and 36-month follow-ups.

The trial included approximately 450 participants of which 91 percent had CLI, a severe form of vascular disease that seriously decreases blood flow to the lower leg arteries.

An estimated 3.4 million people in the United States have CLI today, and the number is estimated to grow to nearly 3.8 million by 2020.[i] CLI is associated with a six-month major amputation rate ranging from 10 percent to 40 percent and with mortality rates as high as 50 percent at five years.[ii]

The Lutonix 014 DCB has been commercially available in Europe, Canada and Australia for treatment of the below-the-knee arteries associated with CLI since 2013.

For more information: www.vivaphysicians.org

References

[i]. Yost, Mary. United States Critical Limb Ischemia by Rutherford Category Prevalence and Markets in Patients and Limbs, The Sage Group. 2018.

[ii]. Teraa M, et al. Critical Limb Ischemia: Current Trends and Future Directions J Am Heart Assoc. 2016;5:e002938.

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init